Evotec SE (EVO) Net Income (2009 - 2026)
Evotec SE (EVO) reported Net Income of -$142756.0 for Q1 2026, down 329.79% on a YoY basis from $62124.8 in Q1 2025, and up 99.88% sequentially from -$120.4 million in Q4 2025.
Evotec SE (EVO) Net Income (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 10 years of Net Income data on file, last reported at -$142756.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income fell 329.79% year-over-year to -$142756.0; the trailing twelve-month figure through Mar 2026 stood at -$120.6 million (up 42.43% YoY), and the FY2025 full-year result was -$120.5 million, up 42.49% from the prior year.
- Net Income grew to -$142756.0 in Q1 2026, from -$120.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $251698.5 in Q3 2022 to a low of -$209.3 million in Q4 2024.
- A 5-year average of -$35.3 million and a median of -$49215.3 in 2025 frame the typical range for Net Income.
- Across the five-year window, Net Income jumped 118.15% in 2023 and tumbled 329.79% in 2026, its largest moves.
- Tracing EVO's Net Income over 5 years: stood at -$179.3 million in 2022, then surged by 49.68% to -$90.2 million in 2023, then sank by 131.96% to -$209.3 million in 2024, then surged by 42.5% to -$120.4 million in 2025, then soared by 99.88% to -$142756.0 in 2026.
- Business Quant data shows EVO's Net Income at -$142756.0 in Q1 2026, -$120.4 million in Q4 2025, and -$50369.9 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | -142,756.04 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -142,756.04 |
| Dec 31, 2025 | -120.37 Mn |
| Sep 30, 2025 | -50,369.91 |
| Jun 30, 2025 | -49,215.34 |
| Mar 31, 2025 | -33,215.35 |
| Dec 31, 2024 | -209.31 Mn |
| Sep 30, 2024 | -43,526.83 |
| Jun 30, 2024 | -102,231.09 |
| Mar 31, 2024 | -22,458.36 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | -42,404.95 |
| Jun 30, 2023 | -46,525.38 |
| Mar 31, 2023 | 14,917.30 |
| Dec 31, 2022 | -179.34 Mn |
| Sep 30, 2022 | 251,698.55 |
| Jun 30, 2022 | -29,810.36 |
| Mar 31, 2022 | -82,202.26 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 158,344.09 |
| Jun 30, 2021 | 72,274.35 |